Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Other Accumulated Expenses (2023 - 2025)

Historic Other Accumulated Expenses for Regen BioPharma (RGBPP) over the last 3 years, with Q4 2025 value amounting to $99776.0.

  • Regen BioPharma's Other Accumulated Expenses rose 14087.1% to $99776.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $99776.0, marking a year-over-year increase of 14087.1%. This contributed to the annual value of $99776.0 for FY2025, which is 37512.38% up from last year.
  • Regen BioPharma's Other Accumulated Expenses amounted to $99776.0 in Q4 2025, which was up 14087.1% from $99776.0 recorded in Q3 2025.
  • Regen BioPharma's Other Accumulated Expenses' 5-year high stood at $99776.0 during Q3 2025, with a 5-year trough of $21000.0 in Q3 2024.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $41423.0 (2023), whereas its average is $48352.6.
  • As far as peak fluctuations go, Regen BioPharma's Other Accumulated Expenses tumbled by 4930.35% in 2024, and later soared by 37512.38% in 2025.
  • Regen BioPharma's Other Accumulated Expenses (Quarter) stood at $41423.0 in 2023, then changed by 0.0% to $41423.0 in 2024, then surged by 140.87% to $99776.0 in 2025.
  • Its last three reported values are $99776.0 in Q4 2025, $99776.0 for Q3 2025, and $21000.0 during Q2 2025.